Although the new and more effective hepatitis C drugs are expensive, they could save the United States and 5 European countries more than $3.2 billion annually, according to estimates reported at Digestive Disease Week 2015.
Although the new and more effective hepatitis C drugs are expensive, they could save the United States and 5 European countries more than $3.2 billion annually, according to estimates reported at Digestive Disease Week 2015, which was held May 16-19 in Washington, DC.
The researchers studied patients being treated with an all-oral combination of ledipasvir and sofosbuvir (LDV/SOF). The high cure rate (between 94% and 99%) and the lessened side effects of this drug combination means reduced absenteeism and improved workplace productivity. Previous treatments had side effects that included fatigue, flu-like symptoms, depression, and lowered blood cell counts.
“Chronic hepatitis C is more than just a problem for the patient—it has a ripple effect that impacts society at large,” Zobair Younossi, MD, chairman of the department of medicine at Inova and the study’s lead author, said in a statement. “While previous reports have found the cost of these drugs as certainly significant, the long term benefits of curing patients with hepatitis C makes this a worthwhile investment.”
Dr Younossi and his colleagues estimated that the average works’ productivity loss of chronic hepatitis C patients was $4954 per employed patient per year in the US and $1129 per employed patient per year in the 5 European countries: France, Germany, Italy, Spain, and the United Kingdom.
They studied data from more than 1900 chronic hepatitis C patients treated with LDV/SOF and found that reduced absenteeism and increased productivity due to the more effective treatment would total approximately $2.65 billion for the US and $556 million for the European countries.
“From a clinical standpoint, we’ve long known about the devastating health impacts that chronic hepatitis C has on a patient,” Dr Younossi said. “But given the significant side effects previously associated with treating the disease, notably fatigue and neuropsychiatric side effects, we were interested in looking at the impact of new treatments on patients’ ability to work, and in a broader sense, how this effects employers and overall economies.”
He plans to conduct additional research to examine data outside of the clinical trial setting in order to evaluate the real-world consequences of a hepatitis C cure. However, Dr Younossi expressed relief at the fact that researchers are beginning to see the bigger picture when it comes to the impact of hepatitis C and its long-term health effects.
The indirect economic gain resulting from a hepatitis C cure “must be considered when assessing the full benefits of treating [chronic hepatitis C] (the clinical benefits, total economic benefits and patient-reported outcomes benefits),” the authors wrote in their abstract.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen